Academic Journal

Keyora Triple-Pathway Collagen Tripeptide Intervention in Dermal Aging: Fine Line Reduction, Elasticity Enhancement, ECM Remodeling, Barrier Repair, Hydration, Brightening, and Antioxidant Protection

Bibliographic Details
Title: Keyora Triple-Pathway Collagen Tripeptide Intervention in Dermal Aging: Fine Line Reduction, Elasticity Enhancement, ECM Remodeling, Barrier Repair, Hydration, Brightening, and Antioxidant Protection
Authors: Jin, Xu
Publisher Information: OSF, 2025.
Publication Year: 2025
Subject Terms: Hydrolyzed collagen tripeptide, Gly-Pro-Hyp, Other Nutrition, Diseases, improving skin firmness and resilience, skin firmness, Dermatology, Skin and Connective Tissue Diseases, Alternative and Complementary Medicine, Facial Rejuvenation, Nutri-cosmetics, Medicine and Health Sciences, Medical Specialties, Nutritional Epidemiology, oral nutria-cosmetics, skin hydration, Other Medicine and Health Sciences, MAPK/ERK, TGF-β/Smad, wrinkle reduction, Primary Care, collagen synthesis, fibroblast signaling, Nutrition, Skin rejuvenation, PepT1 transporter, anti-aging, International and Community Nutrition, Pro + Hyp 25-30%, Life Sciences, Triple anti-aging mechanism, Skin Care, type I collagen, collagen-elastin fiber network, Other Life Sciences, HCTPs, matrix (ECM), Preventive Medicine, Fine Line Reduction, enhance dermal elasticity, Dietetics and Clinical Nutrition, Human and Clinical Nutrition, Biotechnology, Food Science, Gly-Pro-Hyp content (≥50%)
Description: 1) Framework & Rationale This project is based on the Keyora Triple-Pathway Collagen Framework, a comprehensive oral dermal intervention model that integrates structural signaling and substrate supply, elastic-network repair, and barrier–hydration–antioxidant defense. The rationale is that dermal aging is multi-factorial: collagen depletion, elastin fragmentation, extracellular matrix (ECM) collapse, barrier lipid insufficiency, and oxidative imbalance occur simultaneously. A successful strategy must therefore be multi-mechanistic, not single-target. 2) Core Advantages and Mechanistic Highlights (A) Structural signaling & substrate supply - Collagen Tripeptides (1,500 mg/day) - CTP profile advantage: CTP ≥ 30%; Gly-Pro-Hyp–rich (Gly+Pro+Hyp ≥ 50%); Pro/Hyp 12–15%. - Why it matters: These specific tripeptides are highly bioavailable (molecular weight ≈ 500–1,500 Da) and absorbed intact via peptide transporters. They act as both substrates for collagen biosynthesis and signals to fibroblasts, upregulating collagen, elastin, and hyaluronic acid gene expression. - Clinical value: Proven reductions in wrinkle depth, enhanced elasticity, and improved skin smoothness at relatively low doses, avoiding the high-dosage burden of conventional collagen powders. (B) Elastic-network repair - Fish cardiac bulb–derived elastin peptides (20 mg/day) - Unique feature: These peptides retain tropo-elastin core motifs with high recognition by dermal fibroblasts. - Mechanistic advantage: They upregulate elastin, fibrillin, and lysyl oxidase (LOX), enabling elastic fiber reconstruction, something collagen peptides alone cannot achieve. - Clinical value: Restores skin recoil and firmness, directly addressing sagging and loss of resilience — a dimension often missing in collagen-only interventions. (C) Barrier restoration - Ceramide NP 99.5% (2 mg/day) - Purity advantage: Nearly pure (≥ 99.5%) NP form, identical to human skin Ceramide-3. - Mechanistic advantage: Integrates seamlessly into stratum corneum lamellar bilayers with cholesterol and fatty acids (optimal 3:1:1 ratio), reinforcing the barrier and reducing transepidermal water loss (TEWL). - Clinical value: Even at micro-doses, restores barrier integrity, reduces sensitivity, and enhances tolerance — achieving high efficacy with minimal systemic load. (D) Hydration & ECM filling - Hyaluronic Acid (400 kDa, 20 mg/day) - Formulation advantage: Medium molecular weight (400 kDa) chosen for balanced absorption and function. - Mechanistic advantage: Crosses intestinal paracellular routes and is detectable in plasma; stimulates HAS2/3 expression in dermal fibroblasts; integrates into ECM interstices to increase volume and turgor. - Clinical value: Enhances dermal hydration and elasticity, reduces dryness and roughness, and provides visible plumping effects. 3) Integrated Synergy - Collagen tripeptides initiate fibroblast activation and provide substrates. - Elastin peptides ensure elastic network reconstruction, complementing collagen. - Hyaluronic acid restores hydration and volumization, maintaining ECM flexibility. - Ceramide NP rebuilds the barrier, locking in hydration and protecting new structural gains. Together, these four interventions form a closed-loop system — from structure to elasticity to hydration and protection — achieving results beyond single-ingredient supplementation. 4) Clinical Evidence and Consensus - Collagen Tripeptides: Multiple RCTs confirm wrinkle reduction and elasticity improvement with ≥1,000 mg/day dosing. - Elastin peptides: Demonstrated improvements in elasticity and reduction of sagging when combined with collagen peptides. - Hyaluronic Acid (400 kDa): Supported by RCTs showing hydration and wrinkle reduction. - Ceramide NP: Systematic reviews highlight oral ceramide’s efficacy in improving skin moisture, barrier integrity, and tolerance. Consensus: International nutricosmetic research increasingly supports multi-component, low-dose/high-purity interventions as superior to high-dose single compounds. The Keyora Triple-Pathway Framework reflects this consensus, providing a scientifically rational, clinically validated model for oral skin health. 5) Significance This project establishes a next-generation nutricosmetic model that prioritizes: - Mechanistic completeness: collagen, elastin, ECM, barrier, hydration, and antioxidant defense addressed simultaneously. - Bioavailability & purity: selection of peptide forms, 400 kDa HA, and 99.5% ceramide NP ensures optimal absorption and activity. - Synergy, not stacking: each component interlocks, creating a continuum of dermal rejuvenation. - Clinical feasibility: low-dose, safe, and sustainable formulation suitable for long-term use.
Document Type: Article
Language: English
DOI: 10.17605/osf.io/dk8se
Rights: CC BY
Accession Number: edsair.doi...........27ec515a2e4e247e550440d7ba6ee292
Database: OpenAIRE
Description
DOI:10.17605/osf.io/dk8se